BR
Therapeutic Areas
Aclaris Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Zunsemetinib (ATI-450) | Rheumatoid Arthritis | Phase 2b |
| ATI-1777 | Moderate-to-Severe Atopic Dermatitis | Phase 2b |
| ATI-2138 | Inflammatory Bowel Disease / T-cell Mediated Diseases | Phase 1 |
| Sofpironium Bromide | Primary Axillary Hyperhidrosis | Approved |
Leadership Team at Aclaris Therapeutics
DJ
Douglas J. Manion, M.D.
President & Chief Executive Officer
JL
James Loerop, CFA
Chief Business Officer
FR
Frank Ruffo
Chief Financial Officer
DL
David L. Gordon, M.D.
Chief Medical Officer
NW
Neal Walker, D.O.
Co-Founder and Chairman of the Board
AN
Andrew N. Schiff, M.D.
Board Member
KL
Karen L. Smith, M.D., Ph.D.
Board Member
SD
Stuart D. Shanler, M.D.
Former Chief Scientific Officer
CP
Christopher Powala
Former Chief Operating Officer
KB
Kevin B. Leman
Former VP, Commercial Operations